STOCKS TELEGRAPH

Tag: AZRX

  • AzurRx BioPharma, Inc. (AZRX) Stock Suffers Following Upsizing of Previously Announced Public Offering

    AzurRx BioPharma, Inc. (AZRX) stock prices were down 19.66% as of the market closing on July 23rd, 2021, bringing the price per share down to USD$0.5690. Subsequent premarket fluctuations saw the stock rally by 12.48%, bringing it up to USD$0.64.

    AZRX Upsizes Offering

    July 22nd, 2021 saw AZRX stock announce the increasing of the size of its previously announced public offering because of unexpected demand. The underwriter has agreed to purchase on a firm commitment basis 9,090,910 shares of common stock of the company. The price was the same as the public offering, with each share being priced at USD$0.55. The closing of the transaction is expected for July 27th, 2021.

    Details of the Offering

    the offering comes equipped with a 30-day option to purchase up to an additional 1,363,636 shares of common stock at the same public offering price. AZRX stock expects generating USD$5 million in gross proceeds before the deduction of expenses related to the offering and the execution of the option to purchase additional shares. The capital raised is expected to be used to pay milestone payments as per existing license agreements.

    AZRX Stock Hits RESERVOIR Milestone

    Earlier on June 7th, 2021, AZRX stock announced the administration of the first dose of FW-1022 to a volunteer in its ongoing Phase 2 RESERVOIR clinical trial. The proprietary treatment comes in tablet form and is designed to treat Covid-19-related GI infections. The company forecasts topline results from the trial for the first quarter of 2022. This development marks a significant milestone for the company and the development of niclosamide.

    Scope of FW-1022

    With no existing approved treatments for GI infections stemming from Covid-19, the success of AZRX’s development program could help prevent reinfection and, therefore, the spread of Covid-19. FW-1022 also has the potential to treat severe complications that are believed to results from SARS-CoV-2’s ability to hide in reservoirs within the GI tract. The company is confident that its micronized oral niclosamide therapy can target the virus directly in the gut. This will play a critical role in the treatment of Covid-19 patients that suffer from the damage caused by Covid-19-related GI infection.

    Future Outlook for AZRX

    With the world hurtling towards universal immunizations, AZRX stock is poised to capitalize on the burgeoning market. Keen to continue its trajectory of success, the company plans to regain momentum with its added capital and reverse the recent downward trend. Investors are confident in management’s ability to produce significant and sustained increases in shareholder value.

  • Why AzurRx BioPharma Inc. (AZRX) stock plummeted on Thursday?

    AzurRx BioPharma Inc. (AZRX) stock declined 16.03% in after-hours on Thursday, July 22, 2021. The stock closed at $0.59 per share. Before that in the morning session, the share price of the Company lost 4.27% to close Thursday’s session at $0.71. AZRX stock has fallen 38.42% over the last 12 months, and they have moved down 0.06% in the past week. Over the past three months, the stock has lost 15.29%, while over the past six months, it has slid down 42.89%.

    Let’s see is there any recent development behind its plummeting on Thursday?

    AZRX stock expanding the previously announced public offering

    On July 22, 2021, AzurRx BioPharma, Inc announced that the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9,090,910 shares of common stock of the Company, at a price to the public of $0.55 per share, due to high demand. The offer will close on July 27, 2021, subject to satisfaction of customary closing conditions.

    Participation in the recent conferences

    • The Chief Executive Officer of AzurRx, James Sapirstein recently presented the company at the 2021 BIO Digital virtual conference which took place on June 10-11 and June 14-18, 2021.
    • The company also participated in the Rocky Mountain Microcap conference which was held on May 26, 2021.MrSapirstein provided an overview of AzurRx’s business and clinical development programs and discussed anticipated 2021 and early 2022 milestones in the conference.

    First Patient dosed in Phase 2 Clinical Trial of Niclosamide

    On June 07, 2021, AzurRx BioPharma, Inc administered the first dose of FW-1022 to a volunteer in the ongoing Phase 2 RESERVOIR clinical trial. FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections. Topline results from the trial are expected in the first quarter of 2022.

    AZRX stock revealed positive interim data from the phase 2 trial of MS1819 

    On May 13, 2021, AZRX stock announced positive interim data from the first 18 out of 20 patients in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).

    The interim data showed that the combination therapy led to clinically meaningful improvements in the primary efficacy endpoint, the Coefficient of Fat Absorption (CFA), with an average gain of 5.9 points from baseline.

    French Research Tax Credit

    On May 12, 2021, AzurRx SAS, which is a wholly-owned subsidiary of AzurRx BioPharma in France, received approximately 459,000 Euros ($550,000 U.S.) in non-dilutive funding in research tax credits from the French government for its 2020 CIR (French Research Tax Credit).

    Conclusion

    The AZRX stock plummeted after the company announced to increase in the size of its previously announced public offering. we are not sure how the stock market will react on Friday for AZRX.

  • AzurRx BioPharma Inc. (AZRX) stock gains in the pre-market trading. Here’s to know why?

    AzurRx BioPharma Inc. (AZRX) stock gains in the pre-market trading. Here’s to know why?

    AzurRx BioPharma Inc. (AZRX) stock declined by 3.92% at the last trading close whereas the AZRX stock gains by 2.04% in the pre-market trading after AZRX announced that they have started their Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide. AzurRx BioPharma is a clinical-stage biopharmaceutical company focused on developing non-systemic, therapeutic strategies for gastrointestinal (GI) diseases.

    What is happening?

    Today AzurRx BioPharma announced that it has started the RESERVOIR Phase 2 clinical trial of a proprietary oral formulation of micronized niclosamide for the prevention of COVID-19-related GI infections. Patient registration is set to begin in April 2021, with topline results expected in the first quarter of 2022.

    The RESERVOIR Phase 2 clinical trial of AZRX stock is a two-part, two-arm, placebo-controlled study that looks at the safety and effectiveness of micronized oral niclosamide tablets, also known as FW-1022, in patients with COVID-19 GI infection. The primary goals of this study would be to confirm the safety of niclosamide in the treatment of COVID-19 GI infection in patients and also to show that it has the ability to clear the SARS-CoV-2 virus from the GI tract.

    The rate of fecal SARS-CoV-2 virus clearance (rectal swab or stool sample) measured by RT-PCR in the RESERVOIR trial is the primary efficacy indicator, with the niclosamide arm compared to the placebo arm for up to six months. These long-term data suggest that niclosamide treatment can help with COVID-19 symptoms in the long run.

    Furthermore,

    The Chief Medical Officer of AzurRx, Dr. James Pennington said that Long-haul COVID cases are becoming a big problem around the world, and it’s fair to believe the GI tract may be acting as a silent reservoir. Because of its validated safety profile, known efficacy in treating other GI ailments, and exceptional ability to stay in the gut for extended periods of time, the team at AZRX stock assumes that niclosamide is ideally suited to remove these secret GI SARS-CoV-2 reservoirs. AZRX’s micronized niclosamide formulation, which allows for localized concentrations in the gutwill enhance these properties.

  • 26 stocks trending in pre-market

    ‎Bionano Genomics Inc. (BNGO) stock soared 13.81% to $2.39 in the pre-‎market ‎trading following an announcement from the firm that Nasdaq has granted the Company an ‎additional ‎‎180-day compliance period, or until June 28, 2021. The most recent rating by Ladenburg ‎Thalmann, on ‎September 24, 2020, is a Buy. ‎

    Before the trading started on December 31, 2020, fuboTV Inc. (FUBO) is down -‎‎‎2.43% to reach $32.5. It has been trading in a 52-week range of $5.00 to $62.29.‎

    ‎Guardion Health Sciences Inc. (NASDAQ: GHSI) shares are trading down -10.77% ‎at ‎‎$0.5247 at the time of writing. The firm lately revealed the appointment of Bret Scholtes as ‎its ‎President and Chief Executive Officer, and as a member of the Board of Directors. Company’s 52-‎week ‎ranged between $0.17 to $0.74.‎

    ‎Nxt-ID Inc. (NXTD) stock soared 7.1% to $1.81 in the pre-market trading. ‎The ‎most ‎recent rating by Maxim Group, on November 20, 2017, is a Buy.‎

    ‎Castor Maritime Inc. (CTRM) grew over 41.75% at $0.33 in pre-market trading ‎today ‎after receiving 180-day extension from Nasdaq to meet Nasdaq minimum bid price rule. ‎

    ‎Net Element Inc. (NASDAQ: NETE) shares are trading down -5.21% at $15.45 at ‎the ‎time of writing. Company’s 52-week ranged between $1.47 to $20.08. ‎

    ‎Sundial Growers Inc. (SNDL) stock moved down -1.36 percent to $0.4784 in the pre-‎‎market trading following the declaration from the company that it has closed the acquisition of ‎a ‎special purpose vehicle. ‎

    ‎Professional Diversity Network Inc. (IPDN) gained over 14.96% at $3.15 in pre-‎‎market trading Thursday December 31, 2020 after the firm revealed its partnership with ‎Phala ‎Network.‎

    ‎Marathon Patent Group Inc. (MARA) is up more than 7.63% at $11.71 in pre-‎market ‎hours Thursday December 31, 2020. The company recently revealed that it has entered into a ‎contract ‎with Bitmain to purchase 70,000 Antminer S-19 ASIC miners. The stock had dropped over -‎‎7.48% to ‎‎$10.88 in the last trading session.‎

    ‎Riot Blockchain Inc. (RIOT), a Software – Application company, rose about ‎‎4.92% ‎at ‎‎$18.11 in pre-market trading Thursday.‎

    ‎Nano Dimension Ltd. (NNDM) stock moved up 2.09 percent to $9.75 in the pre-‎‎market trading after closing $250 million registered direct offering.‎

    ‎AIkido Pharma Inc. (AIKI) gained over 33.72% at $1.15 in pre-‎‎market ‎trading ‎Thursday December 31, 2020.‎

    ‎Color Star Technology Co. Ltd. (NASDAQ: CSCW) shares are trading down -4.38% ‎at ‎‎$0.8032 at the time of writing after declaring strategic partnership with two UAE ‎companies. ‎Company’s 52-week ranged between $0.31 to $2.06.‎

    ‎IMAC Holdings Inc. (IMAC) stock moved down -4.08 percent to $1.41 in the pre-‎‎market trading after reporting completion of first infusion of Stem Cells in clinical study for ‎the ‎treatment of Bradykinesia due to Parkinson’s disease.‎

    ‎Ampio Pharmaceuticals Inc. (AMPE) stock soared 12.84% to $1.67 in the pre-‎market ‎trading. The firm recently revealed that it has received guidance from the U.S Food & ‎Drug ‎Administration regarding the impact of COVID-19 on its Phase III clinical trial for osteoarthritis of ‎the ‎knee. The most recent rating by ROTH Capital, on December 19, 2019, is a Buy.‎

    ‎Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares are trading up 5.76% ‎at ‎‎$49.4 at the time of writing after the company announced that it would develop a therapeutic spray ‎as ‎a candidate to treat the hereditary lung and digestive-system disease cystic fibrosis. Company’s 52-‎‎week ranged between $8.51 to $129.71. Analysts have a consensus price target of $69. ‎

    Before the trading started on December 31, 2020, Baidu Inc. (BIDU) is up ‎‎3.53% ‎to ‎reach $227.38. It has been trading in a 52-week range of $82.00 to $202.79.‎

    ‎Greenpro Capital Corp. (GRNQ) is up more than 3.11% at $1.99 in pre-market ‎hours ‎Thursday December 31, 2020. The company lately revealed that it intends to set up a Bitcoin ‎‎($BTC) ‎Fund for investment. The stock had jumped over 3.76% to $1.93 in the last trading session.‎

    ‎Onconova Therapeutics Inc. (ONTX) is down more than -3.79% at $0.49 in pre-‎‎market hours Thursday December 31, 2020. The stock had jumped over 18.88% to $0.51 in the ‎last ‎trading session.‎

    ‎JinkoSolar Holding Co. Ltd. (JKS) grew over 2.28% at $65.55 in pre-market ‎trading ‎today. The firm recently revealed annual general meeting 2020 ‎results.‎

    ‎Tonix Pharmaceuticals Holding Corp. (TNXP) lost over -2.76% at $0.6632 in pre-‎‎market trading Thursday December 31, 2020.‎

    ‎Osmotica Pharmaceuticals plc (OSMT) stock moved down -2.13 percent to $4.14 ‎in ‎the pre-market trading after declaring that the U.S. Food and Drug Administration (FDA) has ‎declined ‎to approve one of its products. ‎

    ‎Cinedigm Corp. (CIDM) is down more than -0.69% at $0.62 in pre-‎market ‎hours ‎Thursday December 31, 2020. The stock had dropped over -9.51% to $0.62 in the last ‎trading ‎session.‎

    ‎Novan Inc. (NOVN), a Biotechnology company, dropped about -7.71% at $0.969 ‎in ‎pre-market trading Thursday.‎

    Before the trading started on December 31, 2020, Canaan Inc. (CAN) is ‎up ‎‎25.57% ‎to ‎reach $5.5. It has been trading in a 52-week range of $1.76 to $8.69.‎

    ‎500.com Limited (WBAI) gained over 5.12% at $8.0 in pre-market trading ‎Thursday ‎December 31, 2020. The company recently declared that Mr. Zhaofu Tian has resigned as ‎Chief ‎Technology Officer of the Company due to personal reasons.‎

  • Top 3 Reasons Why AzurRx Biopharma Inc [AZRX] is Gaining Bullish Momentum

    Top 3 Reasons Why AzurRx Biopharma Inc [AZRX] is Gaining Bullish Momentum

    AzurRx Biopharma Inc [NASDAQ:AZRX] has been trading on a bullish channel since May. For the last few days, the stock has gained upside momentum and is currently up by 10%. The stock’s current momentum is driven by increased positive momentum in the market and the fact that AZRX stock has lots of positive news surrounding it at the moment. Some of the key factors that are driving its momentum are as below:

    1. A clinical trial of Cystic Fibrosis

    Today AzurRX has announced that it is initiating a Phase 2b clinical trial for MS1819 in the treatment of Cystic Fibrosis in patients who also have exocrine pancreatic insufficiency. The company has also announced that top-line data from the study is expected in Q1 of 2021. The company also announced that the study aims to understand the efficacy, safety, and tolerability of MS1819.  It also added that its primary endpoint for efficacy is to check for the CFA (coefficient of fat absorption). CEO Steve Boas stated that they believe the clinical protocol offers the right safety environment for those involved.  The positive sentiments from the company’s management and the fact that the treatment is now in phase 2 have given renewed confidence in the stock. This could sustain until the company releases topline data on the treatment in early 2021.

    1. The company is well-capitalized

    When it comes to biopharma stocks, how capitalized a company is matters for the financing of crucial treatment projects. On this front, the company is doing quite well.  It recently raised $15.2 million in a private placement and $6.9 million in a convertible note exchange. AZRX stated that it would use the money on developing its cystic fibrosis therapies for its clinical trials.  Commenting on the two capitalization deals, the CEO stated that they would use the money to fund phase 2 and 3 trials of its projects. With such funding, the company is guaranteed to see the MS1819 project to its conclusive ending. This will play a role in sustaining confidence in this stock going into the foreseeable future, as the market expects a breakthrough on this front.

    1. Strategic partnerships

    Strategic partnerships play into the long-term value growth of an organization. Back in May, the company stated that it had entered into a labeling and packaging agreement with Creapharm clinical supplies. The deal was for the labeling and distribution of MS1819 therapy for treating exocrine pancreatic insufficiency. Commenting on the deal, Creapharm CEO stated that they were happy to be supporting AzurRx in its clinical trials. The support that MS1819 has received through these partnerships has seen investor confidence in its rise over the last months.

    About AzurRX Biopharma Inc

    AzurRx Biopharma Inc is a biopharma that develops treatments for gastrointestinal ailments. It is based in Brooklyn, New York.